• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

    3/15/23 7:58:00 AM ET
    $BIO
    $PACB
    $QSI
    $TMO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations

    Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company.

    Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quantum-Si (NASDAQ:QSI), a next-generation, single-molecule protein sequencing platform company. Prior to that, he served as CEO of Celsee, a novel single-cell genomics platform company that was acquired by Bio-Rad (NYSE:BIO) in 2020. Earlier in his career, Mr. Stark held senior leadership positions at Life Technologies ((acquired by Thermo Fisher Scientific, NYSE:TMO), Pacific Biosciences (NASDAQ:PACB), and Affymetrix (acquired by Thermo Fisher Scientific).

    "The Board is excited to welcome John to Resolve Biosciences to lead our next chapter of growth and success," said Peer M. Schatz, co-founder and Chairman of the Board. "John brings an impressive track record of execution, operational excellence, and successful team building to drive innovation. Throughout his career, John has consistently delivered high-growth results for numerous industry-defining platforms. We look forward to working with him on our quest to shape the future of spatial biology and realize the massive opportunities and vast applications in science and medicine."

    Mr. Schatz added, "We deeply appreciate Jason Gammack for his contributions and leadership of the company as former CEO, including shepherding the company through the COVID-19 pandemic and initial launch of our commercial platform and service offering."

    "I am honored to join Resolve Biosciences as its next Chief Executive Officer," said Mr. Stark. "It is rare to find an opportunity like this to lead a growing company with a transformative technology and a brilliant and passionate team. I'm looking forward to empowering our global partners and customers with the ability to realize the full potential of our Molecular Cartography technology. We are dedicated to delivering best-in-class products that will enable the understanding of the molecular causes of disease and associated immune response."

    About Resolve Biosciences

    Resolve Biosciences is applying the power of Molecular Cartography™ technology to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The complete system features the company's proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity to help scientists detect individual transcripts and rare signals to interpret fundamental biology and to rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, infectious disease, and agriculture. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif. For additional information, visit www.resolvebiosciences.com.

    Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005134/en/

    Get the next $BIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIO
    $PACB
    $QSI
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    Thermo Fisher Scientific Inc
    $TMO
    8/19/2025Outperform
    William Blair
    Thermo Fisher Scientific Inc
    $TMO
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    Thermo Fisher Scientific Inc
    $TMO
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    Thermo Fisher Scientific Inc
    $TMO
    7/9/2025$460.00Buy → Neutral
    UBS
    Quantum-Si Incorporated
    $QSI
    2/7/2025$3.75Buy
    Alliance Global Partners
    Thermo Fisher Scientific Inc
    $TMO
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    Thermo Fisher Scientific Inc
    $TMO
    12/23/2024Sector Perform
    Scotiabank
    More analyst ratings

    $BIO
    $PACB
    $QSI
    $TMO
    SEC Filings

    View All

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    10/20/25 8:07:38 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    10/20/25 8:06:12 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    10/20/25 7:46:05 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the CG MedTech, Diagnostics and Digital Health & Services Forum taking place Thursday, November 20, 2025 at the Westin NY Grand Central. Jeff Hawkins, CEO, will participate in a Fireside Chat on November 20, 2025, at 3:30 PM ET. He and Jeff Keyes, CFO, will also be available for one-on-one meetings throughout the day. A live and archived webcast of the event will be available in the "Investors" section of the Quantum-Si website under Events & Presentations. About Quantu

    10/20/25 8:00:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investor

    10/16/25 5:30:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher's proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively. Working with OpenAI, Thermo Fisher is focusing on accelerating scientific innovation, enhancing productivity and reducing complexity. As part of this collaboration, Thermo Fisher is embedding Open AI APIs (Application Programming Interfaces) into critical areas of its business - ranging from product de

    10/16/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothberg Jonathan M sold $80,112 worth of shares (26,095 units at $3.07) (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    10/17/25 7:05:57 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Weisler Dion J

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    9/30/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Sperling Scott M

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    9/30/25 4:17:08 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    8/13/24 6:01:25 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    8/13/24 6:01:28 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Thermo Fisher upgraded by Barclays with a new price target

    Barclays upgraded Thermo Fisher from Equal Weight to Overweight and set a new price target of $550.00

    9/11/25 8:36:39 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    William Blair initiated coverage on Thermo Fisher

    William Blair initiated coverage of Thermo Fisher with a rating of Outperform

    8/19/25 8:36:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

    7/24/25 9:29:26 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis

    7/28/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

    Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

    7/23/25 9:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Financials

    Live finance-specific insights

    View All

    Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investor

    10/16/25 5:30:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 5, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, ind

    10/13/25 8:00:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 22, 2025

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2025 before the market opens on Wednesday, October 22, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 761271. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under

    10/1/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials